ACES方案治疗难治性或复发性非霍奇金淋巴瘤的疗效观察

The Clinical Observation of ACES Regimen for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

目的应用阿糖胞苷(Ara-c)、顺铂(cisplatin)、足叶乙甙(etoposide),类固醇激素(storid)联合化疗治疗难治性或复发性非霍奇金淋巴瘤(NHL),观察疗效及毒副反应。方法12例难治性或复发性NHL,给予Ara-c 500 mg,d5,顺铂40 mg,d1-3,足叶乙甙(VP16-213)100 mg,d1-4,Dex40 mg,d1-5联合化疗。结果总有效率(CR+PR)为66.6%。毒副反应主要是骨髓抑制,经G-CSF治疗均可恢复。结论与NHL经典方案无交叉耐药的ACES补救方案是治疗难治性或复发性非霍奇金淋巴瘤有效、安全的治疗方案。

Objective To explore the outcome and side-effects in patients with relapsed or refractory non-Hodgkin＇ s lymphoma treated with the ACES regimen （cytarabine, cisplatin, etoposide, storid）. Methods 12 patients with relapsed or refractory non-Hodgkin＇ s lymphoma were treated with the ACES regimen. Results The overall response rate（ CR ＋ PR） was 66.6% . Major toxicity was myelosuppression, and would be treated with G-CSF. Conclusions The ACES regimen which is not cross drug resistant to the classic regimen is an effective and well tolerated salvage regimen for relapsed or refractory non-Hodgkin＇ s lymphoma.